Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  octreotide acetate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 46 for your search:
Start Over
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSMS995AUS38, STOP Trial, NCT00050635
GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: NeuroendoUnit-4, NCT00495846
Phase III Randomized Double-Blind Study of SSTN LAR Given Every 4 Weeks vs Open-Label Standard SSTN Given TID for Symptomatic Control of Malignant Carcinoid Syndrome (Summary Last Modified 09/95)
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-94133A1, NCI-V95-0664
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065713, E-E1295, CLB-9770, SWOG-E1295, NCI-P97-0081, NCT00003057
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069304, NCCTG-N00CA, NCI-P02-0221, N00CA, NCT00033605
Phase III Comparison of TMX vs Sandostatin/TMX in Patients with Metastatic or Recurrent Breast Cancer (Summary Last Modified 09/94)
Phase: Phase III
Type: Treatment
Status: Closed
Age: postmenopausal
Sponsor: NCI
Protocol IDs: NCCTG-893253, MAYO-893253, MCGILL-ET-9110, NCCTG-89-32-53
Phase III Comparison of Octreotide vs 5-FU vs 5-FU/CF in the Treatment of Advanced Adenocarcinoma of the Pancreas
Phase: Phase III
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NCCTG-894352, MAYO-894352, NCCTG-89-43-52
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-0315, CDR0000349441, NCT00075868
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000440922, NCCTG-N04C2, N04C2, NCT00182754
Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 85
Sponsor: Other
Protocol IDs: HCC-327-2000, NCT00121914
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2325, 2006-004507-18, NCT00412061
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2009-00778, CDR0000579151, SWOG-S0518, S0518, U10CA032102, NCT00569127
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSMS995AIC04, NCT00582426
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: postmenopausal
Sponsor: Other
Protocol IDs: MA14, CAN-NCIC-MA14, NCI-V96-1060, CDR0000065135, NCT00002864
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230C2402, 2009-016722-13, EUDRACT 2009-016722-13, NCT01137682
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000064787, NCCTG-947851, NCT00002779
Phase II Study of Octreotide for Meningioma and Meningeal Hemangiopericytoma (Summary Last Modified 04/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-917202, NCI-V96-1073
Phase II Study of the Somatostatin Analogue Sandostatin (SMS 201-995) in Patients with Chondrosarcoma or Osteosarcoma (Summary Last Modified 09/88)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-87094, NCI-V88-0389
Phase II Evaluation of Somatostatin Analogue (Octreotide) for Relapsed Hodgkin's Disease or Cutaneous T-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and older
Sponsor: NCI
Protocol IDs: NCCTG-898251, MAYO-898251, NCCTG-89-82-51
Phase II Pilot Study of Octreotide in the Management of 5-FU Treatment-Related Diarrhea
Phase: Phase II
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-90161, NCI-V91-0041
Phase II Randomized Study of the Somatostatin Analogue Octreotide for Nonfunctioning Pituitary Tumors (Summary Last Modified 08/95)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MGH-88-7553, NCI-V92-0042
Phase II Study of the High-Dose Somatostatin Analogue Octreotide in Patients with Recurrent Extensive Stage Small Cell Lung Cancer (Summary Last Modified 09/94)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-922051, NCCTG-92-20-51
Start Over